Latest Pharma and Biotech News
Pharmaceutical
20 March 2025 Privately-held drugmaker Paratek Pharmaceuticals is to buy specialty pharma Optinose, including its approved product Xhance (fluticasone propionate).
Today's issue
Refine Search
Biotechnology
Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase III trial of its hypoparathyroidism candidate eneboparatide. US biotech Incyte announced new Phase III data for its povorcitinib in the treatment of severe hidradenitis suppurativa that, though meeting trial goals, disappointed investors. Also, USA-based Immunovant released top-line Phase II and Phase III results for its myasthenia gravis (MG) candidate batoclimab. On the deal-making front, France’s Sanofi announced it is acquiring investigational drug DR-0201 from US biotech Dren Bio to expand its immunology pipeline, 23 March 2025
Biotechnology
Danish biotech on Saturday revealed that US pharma major (AbbVie has filed a complaint in the US District Court for the Western District of Washington, naming Genmab, ProfoundBio and former AbbVie employees as defendants. 22 March 2025
Biotechnology
Swedish firm Alligator Bioscience has announced that Dr Sumeet Ambarkhane, chief medical officer, will be leaving the company by end of March 2025, noting that he has played a key role in advancing Alligator’s immune-oncology pipeline and establishing its clinical development organization over the past years. 22 March 2025
Biotechnology
The Trump administration's moves to reduce government funding for the US Food and Drug Administration (FDA) and other agencies, such as the National Institutes of Health, will impact the biotech sector in several important ways, making it likely that companies will seek to combine with peers or be acquired by large pharma players, according to Andrew Goodman, a partner in the M&A practice at law firm Paul Hastings, in a client alert. 22 March 2025
Pharmaceutical
Dizal Pharmaceutical will present new research findings on two of its innovative drugs - sunvozertinib and golidacitinib - at the 2025 European Lung Cancer Congress (ELCC) The studies focus on addressing resistance in non-small cell lung cancer (NSCLC) treatments. 21 March 2025
Biotechnology
Chinese biotech Akeso has reported encouraging early data from a Phase III trial of its bispecific antibody cadonilimab (AK104) in combination with chemoradiotherapy for patients with locally advanced cervical cancer. 21 March 2025
Biotechnology
China's burgeoning biotech R&D capabilities are attracting increasing international attention, with non-Western countries actively seeking partnerships. At the BIOCHINA event in Suzhou on March 13, representatives from South Korean and Russian biotechs expressed strong interest in collaborating with Chinese counterparts. 21 March 2025
Pharmaceutical
The New Drug Application (NDA) for Tazverik (tazemetostat) has been granted conditional approval in China for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) with EZH2 mutation who have received at least two prior systemic therapies, said the drug’s developer, Chinese biopharma Hutchmed. 21 March 2025
Pharmaceutical
UK pharma major AstraZeneca today announced an investment of $2.5 billion in Beijing to establish its sixth global strategic R&D center, as well as major research and manufacturing agreements with local companies that will further advance life sciences in China. 21 March 2025
Pharmaceutical
US healthcare giant Johnson & Johnson has announced manufacturing, research and development and technology investments of more than $55 billion in the USA over the next four years. 21 March 2025
Biotechnology
Monte Rosa Therapeutics, a US biotech developing novel molecular glue degrader (MGD)-based medicines, closed Thursday’s trading more than 5% higher. 21 March 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Swiss pharma giant Novartis’ oral Fabhalta (iptacopan) for the treatment of adults with C3 glomerulopathy (C3G), to reduce proteinuria, making it the first and only treatment approved for this condition and the third US indication for the drug. 21 March 2025
Pharmaceutical
US biotech Rhythm Pharmaceuticals has reacquired the rights to its obesity treatment Imcivree (setmelanotide) in China, including Hong Kong and Macau, after terminating a 2021 licensing agreement with China-based RareStone Group. 21 March 2025
Pharmaceutical
US RNAi therapeutics company Alnylam Pharmaceuticals announced the US Food and Drug Administration (FDA) approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, Amvuttra (vutrisiran). 21 March 2025
Biotechnology
US biotech GRO Biosciences is weighing the way forward for its lead gout program following a quiet restructuring that saw a reduction in research staff and key leadership changes. 21 March 2025
Pharmaceutical
Japanese ophthalmology company Santen Pharmaceutical announced that it will launch Ryjusea Mini solution 0.025% (tropine sulfate hydrate) on April 21, 2025. 21 March 2025
Biotechnology
US pharma major Johnson & Johnson has won US approval for Tremfya (guselkumab) in the treatment of adults with moderately to severely active Crohn’s disease, further expanding the immunology drug’s footprint and reinforcing the company’s efforts to replace revenue from declining Stelara (ustekinumab) sales. 21 March 2025
Biotechnology
Akari Therapeutics, a US biotech developing next-generation bi-functional antibody drug conjugates (ADCs) for the treatment of cancer, has announced the appointment of Abizer Gaslightwala as president and chief executive. 20 March 2025
Pharmaceutical
Today, Cambridge, USA-based clinical-stage oncology company Immuneering announced the appointment of Dr Igor Matushansky as chief medical officer (CMO). 20 March 2025
Biotechnology
Elevation Oncology has decided to discontinue development of EO-3021, a Claudin 18.2 antibody-drug conjugate (ADC) which was being developed for the treatment of advanced, unresectable or metastatic gastric and gastroesophageal junction (GEJ) cancers. 20 March 2025
All news
Biotechnology
Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase III trial of its hypoparathyroidism candidate eneboparatide. US biotech Incyte announced new Phase III data for its povorcitinib in the treatment of severe hidradenitis suppurativa that, though meeting trial goals, disappointed investors. Also, USA-based Immunovant released top-line Phase II and Phase III results for its myasthenia gravis (MG) candidate batoclimab. On the deal-making front, France’s Sanofi announced it is acquiring investigational drug DR-0201 from US biotech Dren Bio to expand its immunology pipeline, 23 March 2025
Biotechnology
Danish biotech on Saturday revealed that US pharma major (AbbVie has filed a complaint in the US District Court for the Western District of Washington, naming Genmab, ProfoundBio and former AbbVie employees as defendants. 22 March 2025
Biotechnology
Swedish firm Alligator Bioscience has announced that Dr Sumeet Ambarkhane, chief medical officer, will be leaving the company by end of March 2025, noting that he has played a key role in advancing Alligator’s immune-oncology pipeline and establishing its clinical development organization over the past years. 22 March 2025
Biotechnology
The Trump administration's moves to reduce government funding for the US Food and Drug Administration (FDA) and other agencies, such as the National Institutes of Health, will impact the biotech sector in several important ways, making it likely that companies will seek to combine with peers or be acquired by large pharma players, according to Andrew Goodman, a partner in the M&A practice at law firm Paul Hastings, in a client alert. 22 March 2025
Pharmaceutical
Dizal Pharmaceutical will present new research findings on two of its innovative drugs - sunvozertinib and golidacitinib - at the 2025 European Lung Cancer Congress (ELCC) The studies focus on addressing resistance in non-small cell lung cancer (NSCLC) treatments. 21 March 2025
Biotechnology
Chinese biotech Akeso has reported encouraging early data from a Phase III trial of its bispecific antibody cadonilimab (AK104) in combination with chemoradiotherapy for patients with locally advanced cervical cancer. 21 March 2025
Biotechnology
China's burgeoning biotech R&D capabilities are attracting increasing international attention, with non-Western countries actively seeking partnerships. At the BIOCHINA event in Suzhou on March 13, representatives from South Korean and Russian biotechs expressed strong interest in collaborating with Chinese counterparts. 21 March 2025
Pharmaceutical
The New Drug Application (NDA) for Tazverik (tazemetostat) has been granted conditional approval in China for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) with EZH2 mutation who have received at least two prior systemic therapies, said the drug’s developer, Chinese biopharma Hutchmed. 21 March 2025
Pharmaceutical
UK pharma major AstraZeneca today announced an investment of $2.5 billion in Beijing to establish its sixth global strategic R&D center, as well as major research and manufacturing agreements with local companies that will further advance life sciences in China. 21 March 2025
Pharmaceutical
US healthcare giant Johnson & Johnson has announced manufacturing, research and development and technology investments of more than $55 billion in the USA over the next four years. 21 March 2025
Biotechnology
Monte Rosa Therapeutics, a US biotech developing novel molecular glue degrader (MGD)-based medicines, closed Thursday’s trading more than 5% higher. 21 March 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Swiss pharma giant Novartis’ oral Fabhalta (iptacopan) for the treatment of adults with C3 glomerulopathy (C3G), to reduce proteinuria, making it the first and only treatment approved for this condition and the third US indication for the drug. 21 March 2025
Pharmaceutical
US biotech Rhythm Pharmaceuticals has reacquired the rights to its obesity treatment Imcivree (setmelanotide) in China, including Hong Kong and Macau, after terminating a 2021 licensing agreement with China-based RareStone Group. 21 March 2025
Pharmaceutical
US RNAi therapeutics company Alnylam Pharmaceuticals announced the US Food and Drug Administration (FDA) approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, Amvuttra (vutrisiran). 21 March 2025
Biotechnology
US biotech GRO Biosciences is weighing the way forward for its lead gout program following a quiet restructuring that saw a reduction in research staff and key leadership changes. 21 March 2025
Pharmaceutical
Japanese ophthalmology company Santen Pharmaceutical announced that it will launch Ryjusea Mini solution 0.025% (tropine sulfate hydrate) on April 21, 2025. 21 March 2025
Biotechnology
US pharma major Johnson & Johnson has won US approval for Tremfya (guselkumab) in the treatment of adults with moderately to severely active Crohn’s disease, further expanding the immunology drug’s footprint and reinforcing the company’s efforts to replace revenue from declining Stelara (ustekinumab) sales. 21 March 2025
Biotechnology
Akari Therapeutics, a US biotech developing next-generation bi-functional antibody drug conjugates (ADCs) for the treatment of cancer, has announced the appointment of Abizer Gaslightwala as president and chief executive. 20 March 2025
Pharmaceutical
Today, Cambridge, USA-based clinical-stage oncology company Immuneering announced the appointment of Dr Igor Matushansky as chief medical officer (CMO). 20 March 2025
Biotechnology
Elevation Oncology has decided to discontinue development of EO-3021, a Claudin 18.2 antibody-drug conjugate (ADC) which was being developed for the treatment of advanced, unresectable or metastatic gastric and gastroesophageal junction (GEJ) cancers. 20 March 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze